Radiological features of programmed cell death-ligand 2-positive lung adenocarcinoma

A single-institution retrospective study

Kazuki Takada, Gouji Toyokawa, Koichi Azuma, Shinkichi Takamori, Tomoko Jogo, Fumihiko Hirai, Tetsuzo Tagawa, Akihiko Kawahara, Jun Akiba, Isamu Okamoto, Yoichi Nakanishi, Yoshinao Oda, Tomoaki Hoshino, Yoshihiko Maehara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim: Programmed cell death-ligand 1 and 2 (PD-L1 and PD-L2) are ligands of the programmed cell death- 1 (PD1) receptor. PD1/PD-L1 inhibitors have shown clinical efficacy in non-small cell lung cancer (NSCLC). However, relatively little is known about the expression of PD-L2, or its association with the clinicopathological features of NSCLC. Here, the radiological features of PD-L2-positive lung adenocarcinoma were evaluated. Materials and Methods: PDL1 and PD-L2 expression were evaluated by immunohistochemical staining of surgically-resected specimens from 393 patients with primary lung adenocarcinoma who underwent preoperative thin-section computed tomography (CT), 222 of whom also underwent 18F-fluorodeoxyglucose positron-emission tomography/CT (18F-FDG-PET/CT). Results: Among the 393 specimens, 132 (33.6%) and 266 (67.7%) were positive for PD-L1 and PD-L2 expression, respectively. Multivariate analysis showed that the absence of surrounding ground glass opacity and the presence of air bronchogram were significantly associated with PD-L2 expression; however, there was no significant association between PD-L2 expression and the consolidation/tumor ratio. In 222 18F-FDG-PET/CT, the maximum standardized uptake value was significantly higher in patients with PD-L2-positive compared to those with PD-L2-negative tumors. Conclusion: PD-L2-positive lung adenocarcinomas are less radiologically malignant and invasive than their PD-L1-positive counterparts.

Original languageEnglish
Pages (from-to)1541-1550
Number of pages10
JournalIn Vivo
Volume32
Issue number6
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Fluorodeoxyglucose F18
Cell death
Tomography
Cell Death
Retrospective Studies
Ligands
Programmed Cell Death 1 Ligand 2 Protein
Non-Small Cell Lung Carcinoma
Programmed Cell Death 1 Receptor
Tumors
Positron emission tomography
Glass
Neoplasms
Opacity
Multivariate Analysis
Air
Consolidation
Staining and Labeling
Cells
Adenocarcinoma of lung

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this

Takada, K., Toyokawa, G., Azuma, K., Takamori, S., Jogo, T., Hirai, F., ... Maehara, Y. (2018). Radiological features of programmed cell death-ligand 2-positive lung adenocarcinoma: A single-institution retrospective study. In Vivo, 32(6), 1541-1550. https://doi.org/10.21873/invivo.11412

Radiological features of programmed cell death-ligand 2-positive lung adenocarcinoma : A single-institution retrospective study. / Takada, Kazuki; Toyokawa, Gouji; Azuma, Koichi; Takamori, Shinkichi; Jogo, Tomoko; Hirai, Fumihiko; Tagawa, Tetsuzo; Kawahara, Akihiko; Akiba, Jun; Okamoto, Isamu; Nakanishi, Yoichi; Oda, Yoshinao; Hoshino, Tomoaki; Maehara, Yoshihiko.

In: In Vivo, Vol. 32, No. 6, 01.11.2018, p. 1541-1550.

Research output: Contribution to journalArticle

Takada, K, Toyokawa, G, Azuma, K, Takamori, S, Jogo, T, Hirai, F, Tagawa, T, Kawahara, A, Akiba, J, Okamoto, I, Nakanishi, Y, Oda, Y, Hoshino, T & Maehara, Y 2018, 'Radiological features of programmed cell death-ligand 2-positive lung adenocarcinoma: A single-institution retrospective study', In Vivo, vol. 32, no. 6, pp. 1541-1550. https://doi.org/10.21873/invivo.11412
Takada, Kazuki ; Toyokawa, Gouji ; Azuma, Koichi ; Takamori, Shinkichi ; Jogo, Tomoko ; Hirai, Fumihiko ; Tagawa, Tetsuzo ; Kawahara, Akihiko ; Akiba, Jun ; Okamoto, Isamu ; Nakanishi, Yoichi ; Oda, Yoshinao ; Hoshino, Tomoaki ; Maehara, Yoshihiko. / Radiological features of programmed cell death-ligand 2-positive lung adenocarcinoma : A single-institution retrospective study. In: In Vivo. 2018 ; Vol. 32, No. 6. pp. 1541-1550.
@article{e777fc7cf6d74b09aa15ff0b055ae970,
title = "Radiological features of programmed cell death-ligand 2-positive lung adenocarcinoma: A single-institution retrospective study",
abstract = "Aim: Programmed cell death-ligand 1 and 2 (PD-L1 and PD-L2) are ligands of the programmed cell death- 1 (PD1) receptor. PD1/PD-L1 inhibitors have shown clinical efficacy in non-small cell lung cancer (NSCLC). However, relatively little is known about the expression of PD-L2, or its association with the clinicopathological features of NSCLC. Here, the radiological features of PD-L2-positive lung adenocarcinoma were evaluated. Materials and Methods: PDL1 and PD-L2 expression were evaluated by immunohistochemical staining of surgically-resected specimens from 393 patients with primary lung adenocarcinoma who underwent preoperative thin-section computed tomography (CT), 222 of whom also underwent 18F-fluorodeoxyglucose positron-emission tomography/CT (18F-FDG-PET/CT). Results: Among the 393 specimens, 132 (33.6{\%}) and 266 (67.7{\%}) were positive for PD-L1 and PD-L2 expression, respectively. Multivariate analysis showed that the absence of surrounding ground glass opacity and the presence of air bronchogram were significantly associated with PD-L2 expression; however, there was no significant association between PD-L2 expression and the consolidation/tumor ratio. In 222 18F-FDG-PET/CT, the maximum standardized uptake value was significantly higher in patients with PD-L2-positive compared to those with PD-L2-negative tumors. Conclusion: PD-L2-positive lung adenocarcinomas are less radiologically malignant and invasive than their PD-L1-positive counterparts.",
author = "Kazuki Takada and Gouji Toyokawa and Koichi Azuma and Shinkichi Takamori and Tomoko Jogo and Fumihiko Hirai and Tetsuzo Tagawa and Akihiko Kawahara and Jun Akiba and Isamu Okamoto and Yoichi Nakanishi and Yoshinao Oda and Tomoaki Hoshino and Yoshihiko Maehara",
year = "2018",
month = "11",
day = "1",
doi = "10.21873/invivo.11412",
language = "English",
volume = "32",
pages = "1541--1550",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Radiological features of programmed cell death-ligand 2-positive lung adenocarcinoma

T2 - A single-institution retrospective study

AU - Takada, Kazuki

AU - Toyokawa, Gouji

AU - Azuma, Koichi

AU - Takamori, Shinkichi

AU - Jogo, Tomoko

AU - Hirai, Fumihiko

AU - Tagawa, Tetsuzo

AU - Kawahara, Akihiko

AU - Akiba, Jun

AU - Okamoto, Isamu

AU - Nakanishi, Yoichi

AU - Oda, Yoshinao

AU - Hoshino, Tomoaki

AU - Maehara, Yoshihiko

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Aim: Programmed cell death-ligand 1 and 2 (PD-L1 and PD-L2) are ligands of the programmed cell death- 1 (PD1) receptor. PD1/PD-L1 inhibitors have shown clinical efficacy in non-small cell lung cancer (NSCLC). However, relatively little is known about the expression of PD-L2, or its association with the clinicopathological features of NSCLC. Here, the radiological features of PD-L2-positive lung adenocarcinoma were evaluated. Materials and Methods: PDL1 and PD-L2 expression were evaluated by immunohistochemical staining of surgically-resected specimens from 393 patients with primary lung adenocarcinoma who underwent preoperative thin-section computed tomography (CT), 222 of whom also underwent 18F-fluorodeoxyglucose positron-emission tomography/CT (18F-FDG-PET/CT). Results: Among the 393 specimens, 132 (33.6%) and 266 (67.7%) were positive for PD-L1 and PD-L2 expression, respectively. Multivariate analysis showed that the absence of surrounding ground glass opacity and the presence of air bronchogram were significantly associated with PD-L2 expression; however, there was no significant association between PD-L2 expression and the consolidation/tumor ratio. In 222 18F-FDG-PET/CT, the maximum standardized uptake value was significantly higher in patients with PD-L2-positive compared to those with PD-L2-negative tumors. Conclusion: PD-L2-positive lung adenocarcinomas are less radiologically malignant and invasive than their PD-L1-positive counterparts.

AB - Aim: Programmed cell death-ligand 1 and 2 (PD-L1 and PD-L2) are ligands of the programmed cell death- 1 (PD1) receptor. PD1/PD-L1 inhibitors have shown clinical efficacy in non-small cell lung cancer (NSCLC). However, relatively little is known about the expression of PD-L2, or its association with the clinicopathological features of NSCLC. Here, the radiological features of PD-L2-positive lung adenocarcinoma were evaluated. Materials and Methods: PDL1 and PD-L2 expression were evaluated by immunohistochemical staining of surgically-resected specimens from 393 patients with primary lung adenocarcinoma who underwent preoperative thin-section computed tomography (CT), 222 of whom also underwent 18F-fluorodeoxyglucose positron-emission tomography/CT (18F-FDG-PET/CT). Results: Among the 393 specimens, 132 (33.6%) and 266 (67.7%) were positive for PD-L1 and PD-L2 expression, respectively. Multivariate analysis showed that the absence of surrounding ground glass opacity and the presence of air bronchogram were significantly associated with PD-L2 expression; however, there was no significant association between PD-L2 expression and the consolidation/tumor ratio. In 222 18F-FDG-PET/CT, the maximum standardized uptake value was significantly higher in patients with PD-L2-positive compared to those with PD-L2-negative tumors. Conclusion: PD-L2-positive lung adenocarcinomas are less radiologically malignant and invasive than their PD-L1-positive counterparts.

UR - http://www.scopus.com/inward/record.url?scp=85055150709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055150709&partnerID=8YFLogxK

U2 - 10.21873/invivo.11412

DO - 10.21873/invivo.11412

M3 - Article

VL - 32

SP - 1541

EP - 1550

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 6

ER -